Format

Send to

Choose Destination
See comment in PubMed Commons below
Am J Kidney Dis. 2014 Jan;63(1):141-7. doi: 10.1053/j.ajkd.2013.06.025. Epub 2013 Sep 8.

Approach to diagnosis and treatment of hypercalcemia in a patient with malignancy.

Author information

  • 1Department of Medicine, University of Virginia Health System, Charlottesville, VA.
  • 2Division of Nephrology and Dialysis, Azienda Ospedaliera "G. Brotzu," Cagliari, Italy.
  • 3Department of Medicine, University of Virginia Health System, Charlottesville, VA. Electronic address: mhr9r@virginia.edu.

Abstract

Hypercalcemia is a common complication of malignancy and portends a worse prognosis. It causes a variety of symptoms in patients, which can range from confusion and polyuria to coma and death. There are 4 broad mechanistic categories to classify hypercalcemia of malignancy: local osteolysis secondary to metastatic cancer or multiple myeloma, excess parathyroid-related hormone, excess 1,25-dihydroxyvitamin D production, and ectopic parathyroid hormone production. Volume expansion with normal saline solution and treatment with intravenous bisphosphonates to decrease osteoclast-mediated bone destruction are effective initial therapies. Calcitonin, gallium nitrate, and corticosteroids can serve as adjunctive therapies. Denosumab is an attractive therapeutic option for refractory cases of hypercalcemia, although more data are required before this therapy can be recommended.

KEYWORDS:

Hypercalcemia; bisphosphonate; cancer; parathyroid hormone–related protein

PMID:
24021907
DOI:
10.1053/j.ajkd.2013.06.025
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center